Stay updated on RAMP204: Avutometinib + Adagrasib in KRAS G12C NSCLC Clinical Trial
Sign up to get notified when there's something new on the RAMP204: Avutometinib + Adagrasib in KRAS G12C NSCLC Clinical Trial page.

Latest updates to the RAMP204: Avutometinib + Adagrasib in KRAS G12C NSCLC Clinical Trial page
- Check3 days agoChange DetectedA new revision tag v3.7.0 was added to the record history, replacing the previous v3.6.6 entry. This reflects an update to the page's history-tracking version.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedA new site revision entry (v3.6.6) was added to the history and the previous revision (v3.6.5) was removed, indicating a software release update to the page rather than changes to trial data or visible content.SummaryDifference0.1%

- Check46 days agoChange DetectedThe record history now shows Revision: v3.6.5 replacing the previous Revision: v3.6.4. This update reflects a new page release being tracked in the history log.SummaryDifference0.1%

- Check60 days agoChange DetectedThe history now shows Revision: v3.6.4, replacing the previous v3.6.3, indicating a new revision entry in the study record history.SummaryDifference0.1%

- Check81 days agoChange DetectedVersion 22 of the study record was released, updating the Study Status to Completed and the Recruitment Status to No longer recruiting, with a revision note of v3.6.3. It also reflects the removal of the previous Active, not recruiting status.SummaryDifference0.6%

- Check88 days agoChange DetectedA new revision entry for v3.6.2 was added to the study's history. This updates the record's version history to reflect the latest change and helps track updates over time.SummaryDifference0.1%

Stay in the know with updates to RAMP204: Avutometinib + Adagrasib in KRAS G12C NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the RAMP204: Avutometinib + Adagrasib in KRAS G12C NSCLC Clinical Trial page.